论文部分内容阅读
目的探讨阿托伐他汀对冠状动脉瘤样扩张患者血清C-反应蛋白水平的影响及意义。方法 30例冠状动脉瘤样扩张患者随机分入阿托伐他汀组及对照组。检测两组患者治疗前后血浆C-反应蛋白水平并比较两组的总有效率。结果两组治疗前后C-反应蛋白水平差异有统计学意义(P<0.05),但阿托伐他汀组较对照组改善更显著(P<0.05)。阿托伐他汀组显效8例,有效5例,无效2例,总有效率86.7%;对照组显效5例,有效5例,无效5例,总有效率66.7%;组间比较差异有统计学意义(P<0.05)。结论阿托伐他汀可显著降低冠状动脉瘤样扩张患者血浆C-反应蛋白水平,改善冠状动脉瘤样扩张患者的预后。
Objective To investigate the effect of atorvastatin on serum C-reactive protein in patients with coronary artery aneurysm-like dilatation. Methods Thirty patients with coronary artery aneurysm-like dilatation were randomly divided into atorvastatin group and control group. Plasma C-reactive protein levels were measured before and after treatment in both groups and the total effective rate was compared between the two groups. Results The difference of C-reactive protein between the two groups before and after treatment was statistically significant (P <0.05), but the atorvastatin group improved more significantly than the control group (P <0.05). In the atorvastatin group, 8 cases were markedly effective, 5 cases were effective, 2 cases were ineffective, and the total effective rate was 86.7%. In the control group, 5 cases were markedly effective, 5 cases were effective, 5 cases were ineffective and the total effective rate was 66.7%. There were statistically significant differences Significance (P <0.05). Conclusions Atorvastatin can significantly reduce the plasma C-reactive protein level in patients with coronary aneurysmal dilatation and improve the prognosis of patients with coronary aneurysmal dilatation.